Weekly Policy Blog: USITC Report Released on TRIPS COVID-19 IP Waiver Expansion
By: Colorado BioScience Association Date: 10/23/2023
In June 2022, World Trade Organization (WTO) member states agreed to waive certain WTO intellectual property protections for COVID-19 vaccines. The U.S. Trade Representative (USTR) has been considerin...
Learn MoreWeekly Policy Blog: CBSA Co-Hosts Facility Tours for State Legislators and Local Leaders
By: Colorado BioScience Association Date: 10/16/2023
Weekly Policy Blog: CBSA Co-Hosts Facility Tours for State Legislators and Local Leaders This month CBSA partnered with both Terumo Blood and Cell Technologies (Terumo BCT) and AGC Biologics to host...
Learn MoreNEWS RELEASE
By: Colorado BioScience Association Date: 10/13/2023
For Immediate Release: October 13, 2023 Colorado BioScience Association to Honor Life Sciences Companies at 20th Annual Awards Celebration, Presented by AGC Biologics En...
Learn MoreWeekly Policy Blog: CBSA Urges Congress to Pass the PASTEUR Act
By: Colorado BioScience Association Date: 09/25/2023
Earlier this month, CBSA participated in PASTEUR Advocacy Day, joining Biotechnology Innovation Organization (BIO) and other organizations, including Infectious Diseases Society of America, Cystic Fib...
Learn MoreEfforts to Control Prescription Drug Pricing Harm Collaborative Work to Advance Patient Care with Health Innovations
By: Colorado BioScience Association Date: 09/18/2023
Elyse Blazevich, President & CEO, Colorado BioScience Association Colorado’s life sciences community and our state leaders share an unwavering commitment to improving patient lives and making sure...
Learn MoreFitzsimons Debuts White Paper on Choosing an Innovation Community, Focus on Talent
By: Colorado BioScience Association Date: 09/18/2023
Fitzsimons Innovation Community presents a new white paper, entitled Choosing an Innovation Community, from a group of thought leaders in the Colorado bioscience and economic development communities....
Learn MoreWeekly Policy Blog: FDA Guidances on 510(k) Submissions; Actuarial Review of Biomarker Testing Coverage Bill
By: Colorado BioScience Association Date: 09/11/2023
FDA Issues Three Guidances on Premarket Notification [510(k)] Program On September 7, 2023, the U.S. Food and Drug Administration’s (FDA’s) Center for Devices and Radiological Health (CDRH) issu...
Learn MoreWeekly Policy Blog: CMS Announces Drugs Subject to Price Controls Under the IRA
By: Colorado BioScience Association Date: 09/05/2023
On August 29, 2023, the Centers for Medicare and Medicaid Services (CMS) announced the first ten prescription drugs that will be subject to price controls in Medicare under the Inflation Reduction Act...
Learn MoreWeekly Policy Blog: CBSA and Partners Provide Recommendations to Improve CMS’ Transitional Coverage for Emerging Technologies (TCET) Proposal
By: Colorado BioScience Association Date: 08/28/2023
CBSA advocates for policies that improve patient access to life-saving novel technologies. This week, CBSA signed on to a letter responding to the long-awaited proposed Transitional Coverage for Emerg...
Learn MoreFitzsimons Innovation Community and Aimco Deepen Co-Commitment to Campus Vision
By: Colorado BioScience Association Date: 08/28/2023
Fitzsimons Innovation Community and Aimco Deepen Co-Commitment to Campus Vision New Partnership Will Accelerate Delivery of Lab Space to Market AURORA, Colo. (August 24, 2023) – Fitzsimons Innovation...
Learn More